{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-033220","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2024-08-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.969466+00:00","generated_at":"2026-05-31T08:26:43.029765+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cocrystal Pharma to present at two investor conferences; outlines near-term clinical milestones","bullets":["Expects to report topline results from influenza A Phase 2a challenge study (CC-42344) in 2024, final report in 2025.","Expects to report topline results from Phase 1 multiple-ascending cohorts for oral norovirus/coronavirus protease inhibitor CDI-988 in late 2024 or early 2025.","Management will present at Virtual Investor Summit Microcap Forum on Aug 20, 2024, and H.C. Wainwright Conference starting Sept 9, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-033220","json":"https://secwatch.observer/filing/0001493152-24-033220.json","markdown":"https://secwatch.observer/filing/0001493152-24-033220.md","text":"https://secwatch.observer/filing/0001493152-24-033220.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224033220/0001493152-24-033220-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315224033220/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:26:43.029765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}